Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 5/20 | 0.43 |
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | JAK3 | P52333 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | CD4 | P01730 | 2/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22613357 | 1.00 | OPRM1 (0.47) | OPRM1OPRK1HTR6ROCK2KAT2B | |
| SCHEMBL10281505 | 0.84 | JAK2 (0.48) | HTR6ROCK2KAT2BJAK2JAK3 | |
| SCHEMBL22613440 | 0.83 | MAPK1 (0.40) | JAK2JAK3ALDH1A1LMNATSHR | |
| SCHEMBL22613437 | 0.83 | MAPK1 (0.40) | JAK2JAK3ALDH1A1LMNATSHR | |
| SCHEMBL2270606 | 0.83 | JAK2 (0.44) | OPRM1OPRK1HTR6ROCK2KAT2B | |
| SCHEMBL2270617 | 0.83 | JAK2 (0.44) | OPRM1OPRK1HTR6ROCK2KAT2B | |
| SCHEMBL2281454 | 0.79 | HTR6 (0.50) | HTR6ROCK2JAK2JAK3ROCK1 | |
| SCHEMBL2226200 | 0.79 | HTR6 (0.50) | HTR6ROCK2JAK2JAK3ROCK1 | |
| SCHEMBL29855198 | 0.78 | HTR6 (0.44) | HTR6JAK2LMNABCHEJAK1 | |
| SCHEMBL22627232 | 0.78 | JAK2 (0.46) | ROCK2KAT2BJAK2JAK3ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220372034-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2022-11-24 | — | — | US | disclosed |
| US-11420966-B2 | Substituted pyrrolopyridines as JAK inhibitors | ACLARIS THERAPEUTICS, INC. | 2022-08-23 | — | — | US | disclosed |
| CN-113727975-A | Substituted pyrrolopyridines as JAK inhibitors | 阿克拉瑞斯治疗股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| US-20200347053-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| WO-2020223728-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. (US) | 2020-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347053-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | OPRM1 3341/4885OPRK1 1308/4885HTR6 4343/4885 |
| US-20220372034-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | OPRM1 3341/4885OPRK1 1308/4885HTR6 4343/4885 |
| US-11420966-B2 | Substituted pyrrolopyridines as JAK inhibitors | JAK1, JAK3, JAK2 | OPRM1 3341/4885OPRK1 1308/4885HTR6 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.